Modus Therapeutics Holding AB
556851-9523ActiveSwedish biotech developing sevuparin for severe inflammatory conditions.
Biotechnology Companymodustx.com
Oversigt
- 1–4
- Medarbejdere
- 500–749t SEK
- Omsætning
- 2011
- Grundlagt
Nøglebeslutningstagere
John Öhd
Chief Executive Officer
@modustx.com+46707XXXXXX
Johan Dighed
Board member
@modustx.com
Viktor Drvota
Chairman
@modustx.com
Michael Forer
Member of the Nomination Committee
@modustx.com
+3 flere kontakter i Funnelfeedr
Beskrivelse
Modus Therapeutics is a Swedish biotechnology company focused on developing novel treatments for severe medical conditions. Their primary focus is the development of their proprietary polysaccharide, sevuparin. Sevuparin is being investigated as a potential therapeutic agent for several high unmet m...